{"page":{"totalFilteredElements":13},"studies":[{"active":true,"description":"A Phase III, Randomized, open-label study evaluating the efficacy and safety of Divarasib and Pembrolizumab versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in patients with previously untreated, KRAS G12C-mutated, advanced or metastatic non-squamous non&#8722;small cell lung cancer","eudractNumber":"2024-518365-10-00","id":11679,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"}],"mutations":[{"name":"ras-Gen","id":"mt_28"},{"name":"KRAS","id":"mt_7"},{"name":"KRAS-G12C","id":"mt_250"}],"nctNumber":"NCT06793215","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2026-01-01T09:29:01+01:00","shortTitle":"KRAScendo 2","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"},{"id":"tl_8","name":"Advanced"},{"id":"tl_9","name":"Metastatic"}]},{"active":true,"description":"<p class=\"MsoNormal\">A Phase 2, Open-Label, Parallel Cohort Study of\nSubcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or\nMetastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer [CR109264]</p>","eudractNumber":"2022-000526-21","id":8484,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"}],"mutations":[{"name":"EGFR","id":"mt_1"}],"nctNumber":"NCT05498428","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2023-03-01T11:55:23+01:00","shortTitle":"PALOMA-2","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"},{"id":"tl_8","name":"Advanced"},{"id":"tl_9","name":"Metastatic"}]},{"active":true,"description":"&#160;A Phase 3, Randomized, Open Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants with relapesd, refractory Multiple Myeloma (KT-US-679-0788,&#160;iMMagine-3)","eudractNumber":"2024-511188-26","id":9859,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT06413498","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-06-13T10:01:57+02:00","shortTitle":"iMMagine-3","therapeutical":true,"therapyLines":[{"id":"tl_8","name":"Advanced"}]}]}